The SARS-CoV-2 Omicron variant of concern is currently the dominant variant circulating globally. Sotrovimab is among the few monoclonal antibodies that has retained its neutralizing activity against Omicron/BA.1 and received Emergency Use Authorization for treatment of patients at risk for progression to severe disease.1,2
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: July 25, 2022.
Published Online: August 1, 2022. doi:10.1001/jama.2022.13854
Corresponding Author: Emma Birnie, MD, PhD, Center for Experimental and Molecular Medicine, Meibergdreef 9, Amsterdam, the Netherlands (firstname.lastname@example.org).
Author Contributions: Drs Birnie and Wiersinga had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Drs Birnie and Biemond contributed equally.
Concept and design: Birnie, de Bree, Welkers, Wiersinga.
Acquisition, analysis, or interpretation of data: Birnie, Biemond, Appelman, Jonges, Welkers, Wiersinga.
Drafting of the manuscript: Birnie, Biemond, Welkers, Wiersinga.
Critical revision of the manuscript for important intellectual content: Birnie, Biemond, Appelman, Jonges, Welkers, Wiersinga.
Statistical analysis: Birnie, Biemond, Welkers.
Obtained funding: de Bree, Wiersinga.
Administrative, technical, or material support: Birnie, Biemond, Appelman, Jonges, Welkers.
Supervision: Birnie, Wiersinga.
Conflict of Interest Disclosures: Dr Wiersinga reported receiving grant support (grant 91716475) from the Netherlands Organization of Scientific Research and personal fees (fees paid to his institution) from GlaxoSmithKline, Pfizer, Sobi, and AstraZeneca. No other disclosures were reported.
Funding/Support: This study was funded by grant 10430142110001 from the Netherlands Organization for Health Research and Development.
Role of the Funder/Sponsor: The Netherlands Organization for Health Research and Development had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: We thank the physicians, nurses, and other health care clinicians at the Amsterdam University Medical Centers and all the patients who participated in this study. The research presented is part of a Dutch cohort study on neutralizing monoclonal antibodies against and other antiviral agents against SARS-CoV-2 (TURN-COVID; NCT05195060). Additional contributions appear in the Supplement.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.